Emerging approaches to bridging discovery science with clinical care in Alzheimer's disease.
作者信息
Sinha Subhash, Gan Li, Pieper Andrew A
机构信息
Helen and Robert Appel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.
Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA; Brain Health Medicines Center, Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Geriatric Psychiatry, GRECC, Louis Stokes VA Medical Center, Cleveland, OH, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA; Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; Department of Neurosciences, Case Western Reserve University, Cleveland, OH, USA.
出版信息
Neurotherapeutics. 2025 Apr;22(3):e00589. doi: 10.1016/j.neurot.2025.e00589.
Abstract
摘要
相似文献
1
Emerging approaches to bridging discovery science with clinical care in Alzheimer's disease.
Neurotherapeutics. 2025 Apr;22(3):e00589. doi: 10.1016/j.neurot.2025.e00589.
2
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice.
Alzheimers Dement (N Y). 2024 Dec 14;10(4):e70013. doi: 10.1002/trc2.70013. eCollection 2024 Oct-Dec.
3
Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery.
Alzheimers Res Ther. 2013 Feb 4;5(1):5. doi: 10.1186/alzrt159. eCollection 2013.
4
Treating Alzheimer's disease by targeting iron.
Br J Pharmacol. 2019 Sep;176(18):3622-3635. doi: 10.1111/bph.14567. Epub 2019 Feb 11.
5
Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation.
Alzheimers Dement. 2017 Mar;13(3):267-273. doi: 10.1016/j.jalz.2016.11.002. Epub 2016 Dec 18.
6
Emerging blood exosome-based biomarkers for preclinical and clinical Alzheimer's disease: a meta-analysis and systematic review.
Neural Regen Res. 2022 Nov;17(11):2381-2390. doi: 10.4103/1673-5374.335832.
7
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
8
Biomarkers of Alzheimer's disease: Bridging the gap between basic science and clinical practice.
J Alzheimers Dis. 2001 Jun;3(3):257-259. doi: 10.3233/jad-2001-3301.
9
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2.
10
Emerging concepts towards a translational framework in Alzheimer's disease.
Neurosci Biobehav Rev. 2023 Sep;152:105246. doi: 10.1016/j.neubiorev.2023.105246. Epub 2023 May 24.
本文引用的文献
1
Nrf2/Bach1 signaling axis: A promising multifaceted therapeutic strategy for Alzheimer's disease.
Neurotherapeutics. 2025 Apr;22(3):e00586. doi: 10.1016/j.neurot.2025.e00586. Epub 2025 Apr 7.
2
Therapeutic modulation of neurogenesis to improve hippocampal plasticity and cognition in aging and Alzheimer's disease.
Neurotherapeutics. 2025 Apr;22(3):e00580. doi: 10.1016/j.neurot.2025.e00580. Epub 2025 Apr 2.
3
Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions.
Neurotherapeutics. 2025 Apr;22(3):e00570. doi: 10.1016/j.neurot.2025.e00570. Epub 2025 Mar 20.
4
Utilization of precision medicine digital twins for drug discovery in Alzheimer's disease.
Neurotherapeutics. 2025 Apr;22(3):e00553. doi: 10.1016/j.neurot.2025.e00553. Epub 2025 Feb 17.
5
Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation.
Neurotherapeutics. 2025 Apr;22(3):e00548. doi: 10.1016/j.neurot.2025.e00548. Epub 2025 Feb 11.
6
Astrocyte and oligodendrocyte pathology in Alzheimer's disease.
Neurotherapeutics. 2025 Apr;22(3):e00540. doi: 10.1016/j.neurot.2025.e00540. Epub 2025 Feb 11.
7
Identification and development of cGAS inhibitors and their uses to treat Alzheimer's disease.
Neurotherapeutics. 2025 Apr;22(3):e00536. doi: 10.1016/j.neurot.2025.e00536. Epub 2025 Jan 31.
8
Perivascular brain clearance as a therapeutic target in cerebral amyloid angiopathy and Alzheimer's disease.
Neurotherapeutics. 2025 Apr;22(3):e00535. doi: 10.1016/j.neurot.2025.e00535. Epub 2025 Jan 30.
9
Mitochondrial dysfunction in Alzheimer's disease: Guiding the path to targeted therapies.
Neurotherapeutics. 2025 Apr;22(3):e00525. doi: 10.1016/j.neurot.2025.e00525. Epub 2025 Jan 17.
10
Senescent brain cell types in Alzheimer's disease: Pathological mechanisms and therapeutic opportunities.
Neurotherapeutics. 2025 Apr;22(3):e00519. doi: 10.1016/j.neurot.2024.e00519. Epub 2025 Jan 6.
Zotero 插件